ACE inhibitors in patients with heart failure

1. Беленков Ю.Н. Хроническая сердечная недостаточность. В кн. «Болезни органов кровообращения». Москва, Медицина -1997, стр. 663-685.

2. Douglas D. Schocken et al. Prevention of Heart Failure. A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group//Circulation. 2008; 117: 2544-2565.

3. Гуревич M.A. В кн. Хроническая сердечная недостаточность. Москва.1997. стр. 4-27.

4. Сидоренко Б.А. Современные подходы к лечению хронической сердечной недостаточности. В кн. Избранные лекции для практикующих врачей. Москва. 2002, стр. 26-36.

5. Garg R., Yusuf S. Overview of randomized trials of angiotensinconverting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Тrials//JAMA 1995; 273: 1450 -6.

6. Pilote L., Abrahamowicz M., Eisenberg M. et al. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure//CMAJ 2008; 178: 1303-11.

7. Gilbert E.M. et al. Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart//Circulation 1993; 88; 472-480.

8. Uretsky B.F., Shaver J.A., Liang C.S. et al. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin-converting enzyme inhibitor lisinopril, with observations on long-term clinical, functional and biochemical responses//Am Heart J. 1988; 116: 480-488.

9. Stone C.K., Uretsky B.F., Linnemeier T.J. et al. Hemodynamic effects of lisinopril after long-term administration in congestive heart failure//Am J Cardiol. 1989; 63: 567-570.

10. Urazi R.C., Fouad F.M., Ceimo J.K. et al. Renin, aldosterone and cardiac decompensation: studies with an oral converting enzyme inhibitor in heart failure//Am J Cardiol. 1979; 44: 1013-1018.

11. Lopez-Sendon J. et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease//EurHeart J. 2004-25, 1454-1470.

12. Shekelle Р.G., Rich M.W., Morton S.C. et al. Efficacy of angiotensin converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender and diabetic status. A meta-analysis of major clinical trials//J Am Coll Cardiol. 2003; 41: 1529-38.

13. Flather M., Yusuf S., Krnber.L, Pfeffer M., Hall A., Murria G. et al. for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients//Lancet 2000; 355: 1575-781.

14. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)//N Engl J Med. 1987; 316: 1429-1435.

15. The SOFVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure//N Engl J Med. 1991; 325: 293-302.

16. Conn J.N., Johnson G., Ziesche S. et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure//N Engl J Med. 1991; 325: 303-10.

17. Burnier M., Brunner H.R.//Lancet. 2000; 355: 637-45.

18. Brown N.J., Vaughn D.E.//Adv Intern Med. 2000; 45: 419-29.

19. Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy//Circulation 1998; 97: 1342-47.

20. Devereux R.B., Palmieri У., Sharpe N. et al. Effects of oncedaily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial//Circulation 2001; 104: 1248-54.

21. Beltman F., Heesen W., Smit A. et al. Twо-year follow-up study to evaluate the reduction of left ventricular mass and diastolic function in mild to moderate diastolic hypertensive patients//J Hypertens Suppl 1998; 16: S. 15-9.

22. Yisuf S., Pfeffer M.A., Swedberg K., Granger K.B., Held P., McMurray J.J.V. et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM Preserved Trial//Lancet 2003; 362: 777-781.

23. Schmieder et al.//JAMA 1996; 275: 1507-1513.

24. Cleland J. et al. Effects of lisinopril on cardiorespiratory neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction//Br Heart J. 1993; 69: 512-515.

25. Jong P., Yisuf S., Rousseau M.F. et al. Effect of enalapril on 12 year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study//Lancet 2003; 361: 1843-8.

26. Schuster E.H., Bulkley В.Н. Expansion of transmural MI: a pathophysiologic factor in cardiac rupture//Circulation. 1979; 60: 1532-1538.

27. Carstensen S. et al. Effects of early enalapril treatment on global and regional wall motion in acute MI. Am Heart J. 1995; 129: 1101 -1108.

28. Edner M. et al. Effect of enalapril initiated early after acute MI on heart failure parameters, with reference to clinical class and echocardiographic determinants//Clin Cardiol. 1996; 19: 543-548.

29. Bonarjee V.V. et al. Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after MI: CONSENSUS II Multi-Echo study group//Am Heart J. 1996; 132: 71-77.

30. Jugdutt B.I. et al. Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine MI//J Am Coll Cardiol. 1992; 19: 713-721.

31. Brown E.J. Jr Swinford R.D., Gadde P., Lillis O. Acute affects of delayed reperfusion on infarct shape and left ventricular volume: a potential mechanism of additional benefits from thrombolytic therapy//J Am Coll Cardiol. 1991; 17: 1641-1650.

32. Hacker M. et al. Comparative effects of low and high doses of the ACE inhibitor lisinopril, on morbidity and mortality in CHF//Circulation. 1999; 100: 2312-2318.

33. Shotan A., Wderhorn J., Hurst A. et al. Risks of ACE inhibition during pregnancy: experimental and clinical evidence, potential mechanisms and recommendations for use//Am J Med. 1994; 96: 451-456.

34. David D. et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor-associated cough//Am J Ther 1995; 2: 806-813.

35. CONSENSUS trial group. Effects of enalapril on long-term mortality in severe congestive heart failure//Am J Cardiol. 1992; 69: 103-110.